Navidea Biopharmaceuticals, Inc.
NAVB · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $66 | $532 | $915 | $27 |
| % Growth | -87.6% | -41.9% | 3,337.6% | – |
| Cost of Goods Sold | $185 | $199 | $1 | $7 |
| Gross Profit | -$170 | $333 | $914 | $20 |
| % Margin | -259.4% | 62.6% | 99.9% | 75% |
| R&D Expenses | $5,970 | $5,142 | $4,930 | $5,338 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $7,962 | $7,450 | $6,695 | $6,275 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$51 | -$199 | $0 | -$631 |
| Operating Expenses | $13,881 | $12,393 | $11,625 | $10,982 |
| Operating Income | -$14,051 | -$12,060 | -$10,711 | -$10,963 |
| % Margin | -21,402.1% | -2,269.1% | -1,170.6% | -41,184.6% |
| Other Income/Exp. Net | -$1,126 | $346 | -$11 | $18 |
| Pre-Tax Income | -$15,177 | -$11,715 | -$10,722 | -$10,945 |
| Tax Expense | $0 | $16 | $0 | $1 |
| Net Income | -$15,177 | -$11,731 | -$10,722 | -$10,946 |
| % Margin | -23,117.6% | -2,207.1% | -1,171.8% | -41,120.9% |
| EPS | -0.59 | -0.4 | -0.48 | -0.76 |
| % Growth | -47.5% | 16.7% | 36.8% | – |
| EPS Diluted | -0.56 | -0.4 | -0.48 | -0.76 |
| Weighted Avg Shares Out | 29,344 | 29,344 | 23,896 | 14,393 |
| Weighted Avg Shares Out Dil | 30,902 | 29,344 | 23,896 | 14,393 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $11 | $25 |
| Interest Expense | $1,098 | $6 | $0 | $0 |
| Depreciation & Amortization | $96 | $199 | $70 | $145 |
| EBITDA | -$13,983 | -$11,507 | -$10,641 | -$10,818 |
| % Margin | -21,298.7% | -2,164.9% | -1,162.9% | -40,641.7% |